Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238061 | 0.90 | HTR2C (0.51) | HTR2CMTNR1AMTNR1BGAAMAPK1 | |
| SCHEMBL5238069 | 0.90 | HTR2C (0.51) | HTR2CMTNR1AMTNR1BGAAMAPK1 | |
| SCHEMBL5231348 | 0.89 | HTR2C (0.49) | HTR2CMTNR1AMTNR1BGAAMAPK1 | |
| SCHEMBL5233121 | 0.87 | GAA (0.48) | HTR2CGAAMAPK1HTR6ALDH1A1 | |
| SCHEMBL5229139 | 0.80 | HTR2C (0.38) | HTR2CGAAMAPK1ALDH1A1CYP2D6 | |
| SCHEMBL5231203 | 0.77 | CYP2D6 (0.36) | HTR2CGAAMAPK1CYP2D6 | |
| SCHEMBL6640170 | 0.77 | HTR2C (0.51) | HTR2CMTNR1AMTNR1BMAPK1HTR6 | |
| SCHEMBL12579952 | 0.72 | HTR2C (0.71) | HTR2CMTNR1AMTNR1BGAAMAPK1 | |
| SCHEMBL5233126 | 0.70 | HTR2C (0.82) | HTR2CMTNR1AMTNR1BGAAMAPK1 | |
| SCHEMBL7163373 | 0.70 | HTR2C (0.76) | HTR2CMTNR1AMTNR1BGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347979-B1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1347979-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6610685-B2 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020160997-A1 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | F.HOFFANN-LA ROCHE AG (CH) | 2002-10-31 | — | — | US | disclosed |
| WO-2002051844-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160997-A1 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | PNLIP, LIPA, LPL | HTR2C 502/4885MTNR1A 320/4885MTNR1B 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.